Lenar

Omeprazole, the active ingredient in Lenar, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is employed in the management of acid‑related gastrointestinal conditions such as reflux disease and ulcers.

GNH USA supplies Lenar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions globally and markets.

Omeprazole is a proton pump inhibitor used to manage disorders associated with excess gastric acid secretion. - Gastro‑esophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by reducing acid exposure. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence through sustained acid suppression. - Helicobacter pylori eradication regimens: enhances the effectiveness of antibiotic combinations by creating a less acidic gastric environment.

Omeprazole is generally well tolerated, but a range of adverse reactions have been reported. Common Side Effects: - Headache: mild to moderate pain often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Nausea: feeling of sickness without vomiting. - Abdominal pain: discomfort or cramping in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements. Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis requiring immediate medical attention. - Clostridioides difficile infection: severe colitis associated with antibiotic‑like diarrhea. - Low magnesium levels: hypomagnesemia that can cause muscle cramps or cardiac arrhythmia. - Liver enzyme elevation: hepatotoxicity manifesting as jaundice or abnormal labs.

When prescribing omeprazole, clinicians should consider several safety aspects to minimize risk. - Assess renal function: dose adjustment may be needed in severe impairment. - Use caution in the elderly: increased susceptibility to fractures and infections. - Avoid concomitant use with clopidogrel: may reduce antiplatelet effectiveness. - Monitor magnesium levels: long‑term therapy can lead to hypomagnesemia. - Review for potential drug‑induced infections: prolonged acid suppression may predispose to pneumonia or C. difficile. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several medicines; awareness of these interactions helps ensure safe co‑administration. Major Interactions (Avoid): - Clopidogrel: reduced conversion to active metabolite, decreasing antiplatelet effect. - Atazanavir: decreased absorption leading to loss of antiviral efficacy. - HIV protease inhibitors (e.g., ritonavir): lowered plasma concentrations, compromising HIV therapy. Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels, risk of toxicity. - Methotrexate: decreased renal clearance, may raise toxicity risk. - Ketoconazole: reduced absorption, may need alternative antifungal therapy.